Business Wire

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement ...
Business Wire

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab ...
Monthly Prescribing Reference

First-Line Datopotamab Deruxtecan Improves PFS, OS in Metastatic TNBC

Findings showed datopotamab deruxtecan significantly improved PFS and OS vs chemotherapy. Topline data were announced from a phase 3 trial evaluating datopotamab deruxtecan-dlnk as a first-line ...
Nasdaq

Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

TROPION-Lung01, evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial ...
Seeking Alpha

Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

First Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 trial Twelfth ...
Healio

Datopotamab deruxtecan fails to extend OS vs. chemotherapy in advanced breast cancer

Please provide your email address to receive an email when new articles are posted on . Datopotamab deruxtecan failed to extend OS vs. chemotherapy for adults with advanced breast cancer, according to ...
The American Journal of Managed Care

TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention ...
Nasdaq

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors Datopotamab ...
Seeking Alpha

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Based on TROPION-Lung05 Phase II trial and supported by data from TROPION-Lung01 Phase III trial WILMINGTON, Del.--(BUSINESS WIRE)-- Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough ...